Printer Friendly

FOREST LABORATORIES ANNOUNCES LICENSE TO POTENTIAL NEW ALZHEIMER'S TREATMENT

 NEW YORK, Aug. 17 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that it had licensed the exclusive rights to AF102B, a muscarinic agonist from the Pharmaceutical Division of Snow Brand Milk Products, Ltd., of Japan for North America. Forest will also have comarketing rights for the United Kingdom and Ireland. AF102B is a selective M(1) agonist acting at post-synaptic, cholinergic receptors. It may be useful in the management of memory loss and disorientation in Alzheimer's Disease through stimulation of the post-synaptic receptors to compensate for the reduced amounts of acetylcholine characteristic of patients with Alzheimer's Disease.
 AF102B is currently in Phase II clinical development in Japan. Phase I studies have been carried out in the United States under an IND. Forest will continue the Phase I studies and initiate Phase II trials beginning this Fall.
 Howard Solomon, president of Forest, stated that: "AF102B expands Forest's development of drugs for the treatment of Alzheimer's Disease. Its potential for alleviating memory impairment depends on a different mode of action than Synapton, our cholinesterase inhibitor currently in Phase III trials. It is possible, therefore, that both drugs may be used concurrently."
 -0- 8/17/93
 /CONTACT: Kenneth E. Goodman, vice president-finance, 212-421-7850, of Forest Laboratories/
 (FRX)


CO: Forest Laboratories, Inc. ST: New York IN: MTC SU: PDT

SM-LG -- NY013 -- 3405 08/17/93 08:51 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 17, 1993
Words:231
Previous Article:TJ SYSTEMS ANNOUNCES LARGEST LEASE AGREEMENT IN COMPANY HISTORY; GRUMMAN EQUIPMENT LEASE EXCEEDS $4 MILLION
Next Article:COREL CORPORATION RELEASES CORELDRAW 3 FOR UNIX
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters